XML 35 R25.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Restructuring, Impairment, and Related Charges, Net (Tables) | 6 Months Ended
--- | ---
Sep. 30, 2022
Restructuring and Related Activities [Abstract] |
Restructuring, Impairment, and Related Costs | Restructuring, impairment, and related charges, net, for the three months ended September 30, 2022 and 2021 consisted of the following:
| Three Months Ended September 30, 2022
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Severance and employee-related costs, net | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 2 |  |  | $ | (5) |  |  | $ | (3) |
Exit and other-related costs (1) | — |  |  | 1 |  |  | 1 |  |  | 6 |  |  | 14 |  |  | 22 |
Asset impairments and accelerated depreciation | 3 |  |  | 6 |  |  | — |  |  | 1 |  |  | 1 |  |  | 11 |
Total | $ | 3 |  |  | $ | 7 |  |  | $ | 1 |  |  | $ | 9 |  |  | $ | 10 |  |  | $ | 30 |
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
| Three Months Ended September 30, 2021
(In millions) | U.S. Pharmaceutical (1) |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate (1) |  | Total
Severance and employee-related costs, net | $ | — |  |  | $ | (1) |  |  | $ | 1 |  |  | $ | (2) |  |  | $ | 1 |  |  | $ | (1) |
Exit and other-related costs (2) | 2 |  |  | 1 |  |  | — |  |  | 1 |  |  | 6 |  |  | 10 |
Asset impairments and accelerated depreciation | 8 |  |  | — |  |  | 1 |  |  | 2 |  |  | 12 |  |  | 23 |
Total | $ | 10 |  |  | $ | — |  |  | $ | 2 |  |  | $ | 1 |  |  | $ | 19 |  |  | $ | 32 |
(1)Includes costs related to the transition to a partial remote work model described above. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Restructuring, impairment, and related charges, net, for the six months ended September 30, 2022 and 2021 consisted of the following:
| Six Months Ended September 30, 2022
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 3 |  |  | $ | — |  |  | $ | — |  |  | $ | 2 |  |  | $ | (6) |  |  | $ | (1) |
Exit and other-related costs (1) | 1 |  |  | 3 |  |  | 2 |  |  | 8 |  |  | 29 |  |  | 43 |
Asset impairments and accelerated depreciation | 3 |  |  | 11 |  |  | — |  |  | 1 |  |  | (4) |  |  | 11 |
Total | $ | 7 |  |  | $ | 14 |  |  | $ | 2 |  |  | $ | 11 |  |  | $ | 19 |  |  | $ | 53 |
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
| Six Months Ended September 30, 2021
(In millions) | U.S. Pharmaceutical (1) |  | Prescription Technology Solutions (1) |  | Medical-Surgical Solutions (1) |  | International (2) |  | Corporate (1) |  | Total
Severance and employee-related costs, net | $ | 2 |  |  | $ | (1) |  |  | $ | 1 |  |  | $ | 10 |  |  | $ | 1 |  |  | $ | 13 |
Exit and other-related costs (3) | 4 |  |  | 2 |  |  | 2 |  |  | 15 |  |  | 27 |  |  | 50 |
Asset impairments and accelerated depreciation | 16 |  |  | 17 |  |  | 5 |  |  | 36 |  |  | 53 |  |  | 127 |
Total | $ | 22 |  |  | $ | 18 |  |  | $ | 8 |  |  | $ | 61 |  |  | $ | 81 |  |  | $ | 190 |
(1)Includes costs related to the transition to a partial remote work model described above. (2)Includes costs related to the transition to a partial remote work model described above, U.K. operating model and cost optimization efforts, and costs for optimization programs in Canada. (3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Schedule of Restructuring and Asset Impairment Charges | The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the six months ended September 30, 2022:
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Balance, March 31, 2022 (1) | $ | 11 |  |  | $ | 3 |  |  | $ | 1 |  |  | $ | 56 |  |  | $ | 59 |  |  | $ | 130 |
Restructuring, impairment, and related charges, net | 7 |  |  | 14 |  |  | 2 |  |  | 11 |  |  | 19 |  |  | 53 |
Non-cash charges | (3) |  |  | (11) |  |  | — |  |  | (1) |  |  | 4 |  |  | (11) |
Cash payments | (3) |  |  | (3) |  |  | (2) |  |  | (6) |  |  | (25) |  |  | (39) |
Other (2) | (1) |  |  | — |  |  | — |  |  | (24) |  |  | 1 |  |  | (24) |
Balance, September 30, 2022 (3) | $ | 11 |  |  | $ | 3 |  |  | $ | 1 |  |  | $ | 36 |  |  | $ | 58 |  |  | $ | 109 |
(1)As of March 31, 2022, the total reserve balance was $130 million, of which $58 million was recorded in “Other accrued liabilities,” $36 million was recorded in “Liabilities held for sale,” and $36 million was recorded in “Other non-current liabilities” in the Condensed Consolidated Balance Sheet. (2)Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. For the Company’s International segment, other also includes a reduction of the liability related to the sale of the U.K. disposal group in April 2022, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” (3)As of September 30, 2022, the total reserve balance was $109 million, of which $60 million was recorded in “Other accrued liabilities,” $22 million was recorded in “Liabilities held for sale,” and $27 million was recorded in “Other non-current liabilities” in the Condensed Consolidated Balance Sheet.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4) -URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(2)) -URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration